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Angiogenesis not only depends on endothelial cell (EC) invasion and proliferation, but also 
requires pericyte coverage of vascular sprouts for vessel stabilization.1,2 These processes 
are coordinated by Vascular Endothelial Growth Factor (VEGF) and Platelet Derived 
Growth Factor (PDGF) through their cognate receptors on ECs and vascular smooth muscle 
cells (VSMCs), respectively.3,4 PDGF induces neovascularization by priming VSMCs/
pericytes to release pro-angiogenic mediators.5–7 While VEGF directly stimulates EC 
proliferation and migration, its role in pericyte biology is less clear. Here, we define a role 
for VEGF as an inhibitor of neovascularization based on its capacity to disrupt VSMC 
function. Specifically, under conditions of PDGF-mediated angiogenesis, VEGF ablates 
pericyte coverage of nascent vascular sprouts leading to vessel destabilization. At the 
molecular level, VEGF-mediated activation of VEGF-R2 suppresses PDGF-Rβ signaling in 
VSMCs through the assembly of a previously undescribed receptor complex consisting of 
PDGF-Rβ and VEGF-R2. Inhibition of VEGF-R2 not only prevents assembly of this 
receptor complex but also restores angiogenesis in tissues exposed to both VEGF and 
PDGF. Finally, genetic deletion of tumor cell VEGF disrupts PDGF-Rβ/VEGF-R2 complex 
formation and increases tumor vessel maturation. These findings underscore the importance 
of VSMCs/pericytes in neovascularization8–9 and reveal a dichotomous role for VEGF and 
VEGF-R2 signaling as both a promoter of EC function and a negative regulator of VSMCs 
and vessel maturation.
VEGF and PDGF contribute to angiogenesis and vessel stabilization by activating ECs and 
VSMCs respectively, suggesting that a combination of these factors might elicit a 
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synergistic response. To directly test this in angiogenesis models, PDGF, VEGF or both 
were mixed with Matrigel and implanted subcutaneously into mice or topically applied to 
the CAM of 10-day old chick embryos. As expected PDGF-BB or VEGF, at an optimal 
angiogenic dose (Supplementary Fig. 1a–b), promotes robust neovascularization (Fig. 1a). 
Surprisingly, the combination of these cytokines results in complete suppression of 
angiogenesis (Fig. 1a). Inhibition of angiogenesis is not likely due to excessive proliferation 
of mural or stromal cells, since PDGF or VEGF each combine with bFGF to produce an 
increased angiogenic response (Fig. 1a).10 Thus, a specific antagonistic relationship exists 
between PDGF and VEGF during neovascularization.
We next considered whether PDGF or VEGF receptors contribute to the antagonistic effects 
of combined VEGF/PDGF treatment on neovascularization. Following PDGF receptor 
blockade, suppression of angiogenesis is observed in the presence of either growth factor 
(Fig. 1b), consistent with a role for PDGF in the release of pro-angiogenic factors and the 
recruitment of VSMCs/pericytes to nascent EC sprouts.11–12 While combined PDGF/
VEGF stimulation leads to the appearance of tenuous and small caliber vascular sprouts on 
CAMs at 48 hours, a complete absence of new vessel growth is evident on CAMs by 72 
hours (Fig. 1b)(Supplementary Fig. 1c). Thus, combined PDGF/VEGF treatment initiates 
vessel sprouting but not a durable vascular response.
To assess the role of VEGF-R2 as a negative regulator of pericyte function, Matrigel and 
CAM tissues were treated with either a VEGF-R2 kinase inhibitor or anti-VEGF-R2 and 
stimulated with PDGF, VEGF or both. As expected, either inhibitor disrupts VEGF- but not 
PDGF-mediated angiogenesis in both models (Figure 1b).13 Interestingly, following PDGF/
VEGF treatment, VEGF-R2 inhibition restores angiogenesis to a level achieved with either 
growth factor alone (Fig. 1b), suggesting that under conditions of VEGF/PDGF stimulation, 
VEGF-R2 negatively regulates neovascularization. To validate these observations, mice 
were injected with Matrigel impregnated with growth factors, as well as adenovirus 
expressing an inactive truncation mutant of the VEGF-R2 receptor. Gene delivery to the 
vascular compartment suppresses VEGF-R2 phosphorylation in these tissues 
(Supplementary Fig. 2a–b). Importantly, the VEGF-R2 truncation mutant restores the 
angiogenic response following PDGF/VEGF stimulation without affecting PDGF-mediated 
angiogenesis (Fig. 1c). These studies demonstrate that, in the presence of both VEGF and 
PDGF, VEGF-R2 can limit pro-angiogenic events.
We next considered the effect of VEGF treatment on PDGF-stimulated pericyte recruitment 
to nascent vessels during angiogenesis. As expected, PDGF treatment alone produces a 
robust influx of alpha-smooth muscle actin expressing (α-SMA+; VSMC/pericyte marker) 
cells to the surface of patent blood vessels (Fig. 2a).5 However, stimulation of tissues with 
PDGF/VEGF results in a reduction in vascular pericyte coverage compared to tissues treated 
with PDGF alone. Importantly, pericyte coverage and neovascularization are restored 
following VEGF-R2 inhibition (Fig. 2a), suggesting that VSMC/pericyte VEGF-R2 
negatively regulates this response.
To assess whether VSMC function could be influenced by the combination of PDGF and 
VEGF we examined the effects of these growth factors on proliferation and migration in 
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primary human VSMCs in vitro. Although PDGF induces VSMC proliferation and 
migration, exposure to both PDGF and VEGF results in a complete suppression of these 
responses (Fig. 2b). In contrast, Human Umbilical Vein ECs (HUVECs), which express 
VEGFR-2 but not PDGF receptors and Normal Human Dermal Fibroblasts (NHDFs), which 
express PDGF but not VEGF receptors (Supplementary Fig. 3a), exhibit robust migration 
and proliferation in the presence of PDGF/VEGF. Similar results were obtained with a wide 
range of other ECs and VSMC/pericytes (Supplementary Fig. 4). Importantly, VSMCs pre-
treated with a VEGF-R2-inhibitor or subjected to siRNA-mediated knockdown of VEGF-
R2, but not VEGF-R1, demonstrate complete reversal of PDGF/VEGF-mediated 
suppression of cell migration and proliferation (Fig. 2c). This may be explained by the 
finding that VEGF significantly attenuates PDGF-induced pp60-Src and ERK signaling 
(Supplementary Fig. 5). Importantly, co-stimulation with bFGF and PDGF does not 
suppress PDGF-mediated VSMC chemotaxis (data not shown), further supporting a specific 
relationship between VEGF and PDGF.
The antagonistic results of PDGF/VEGF treatment do not result from competition for 
receptor occupancy since treatment with a range of VEGF doses fails to suppress PDGF 
stimulation of PDGF-Rβ in NHDFs, which lack VEGF-R2 (data not shown). Thus, it 
appears that VEGF-ligation of VEGF-R2 in VSMC’s leads to inactivation of PDGF-Rβ, the 
dominant PDGF receptor on these cells. To test this possibility, VSMCs were exposed to 
varying concentrations of VEGF (in the presence or absence of PDGF) and the PDGF-Rβ 
phosphorylation (activation) status was evaluated. While VEGF alone fails to induce PDGF-
Rβ phosphorylation, VEGF suppresses PDGF-mediated PDGF-Rβ tyrosine phosphorylation 
by fivefold, which can be reversed by PDGF titration (Supplementary Fig. 6a–b). 
Importantly, VEGF-121, which lacks a heparin-binding domain, also suppresses PDGF-
mediated activation of PDGF-Rβ (Supplementary Fig. 6c). To evaluate the requirement of 
VEGF receptors for this process we subjected VSMCs to VEGF-R1 or VEGF-R2 siRNA-
mediated knock-down and analyzed the effect of PDGF/VEGF co-stimulation on PDGF-Rβ 
activity. Knock-down of VEGF-R2 but not VEGF-R1 abrogates the VEGF-mediated 
inactivation of PDGF-Rβ, indicating that VEGF-R2 is essential for VEGF-mediated 
suppression of PDGF signaling in VSMCs (Fig. 3a). VEGF-R2 kinase inhibition also 
restores PDGF-Rβ phosphorylation in cells exposed to PDGF/VEGF, providing further 
evidence that VEGF-R2 negatively regulates PDGF-Rβ (Supplementary Fig. 7a). Thus, co-
stimulation of VSMCs with PDGF/VEGF results in crosstalk between the cognate receptors 
for these ligands, leading to suppression of PDGF signaling.
To further define the underlying mechanism of VEGF-R2-dependent inhibition of PDGF-Rβ 
activity, VEGF-R2 or VEGF-R2(Δ450C) were expressed in NHDF cells, which lack VEGF-
R2. VEGF induces phosphorylation of wild-type VEGF-R2 but not the truncated derivative 
(Supplementary Fig. 8a–b). NHDF cells transduced with VEGF-R2, or VEGF-R2(Δ450C) 
demonstrate equivalent phosphorylation of PDGF-Rβ in response to PDGF alone (Fig. 3b). 
However, when NHDFs expressing VEGF-R2 were stimulated with VEGF/PDGF, PDGF-
Rβ exhibits decreased phosphorylation relative to cells expressing truncated VEGF-R2. This 
is associated with a concomitant reduction in proliferation and cell migration, relative to 
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cells exposed to either cytokine alone, demonstrating that VEGF-R2 expression is sufficient 
to inhibit PDGF-dependent function in VSMCs. (Fig. 3b).
Given the functional crosstalk between VEGFR2 and PDGF-Rβ in VSMCs, we evaluated 
whether these receptors interact directly by performing reciprocal co-immunoprecipitation 
studies. Importantly, treatment of VSMCs with PDGF/VEGF results in the formation of a 
previously un-described VEGF-R2/PDGF-Rβ complex, whereas no interaction is detected 
following exposure of cells to either growth factor alone (Fig. 3c). The same biochemical 
interaction was not detected with PDGF-Rα (Supplementary Fig. 9a). Furthermore, pre-
treatment of VSMCs with a VEGF-R2 inhibitor attenuates VEGF-R2/PDGF-Rβ complex 
formation, suggesting a requirement for VEGF-R2 activity. Similar findings are observed in 
the pericyte-like 10T1/2 cell line which is often used to approximate pericytes in vitro, and 
which have been found to exhibit growth suppression in co-culture with endothelial cells 
(Supplementary Fig. 9b).14,15 As a final biochemical confirmation, growth factor-
dependent PDGF-Rβ/VEGF-R2 complex formation was identified in HEK-293 cells 
ectopically expressing both VEGF-R2 and PDGF-Rβ (Supplementary Fig. 9c). To confirm 
these findings by using a cell biological approach, we performed Proximity Ligation 
Analysis (PLA) which depicts close proximity of cellular molecules and demonstrates a 5-
fold increase in the VEGF-R2/PDGF-Rβ interaction following PDGF/VEGF co-stimulation, 
relative to cells stimulated with either growth factor alone (Supplementary Fig. 10). To 
further characterize this interaction, NHDFs were transduced with full length or VEGF 
R2(Δ450C). As demonstrated in VSMCs, expression of full length VEGF-R2 but not the 
truncation mutant results in the formation of a VEGR-R2/PDGF-Rβ complex (following 
dual cytokine stimulation only) (Fig. 3d). These results demonstrate a requirement for the 
VEGF-R2 C-terminus in the VEGR-R2/PDGF-Rβ interaction.
We next transduced NHDFs with VEGF-R2(Y1052/1057F), which fails to undergo auto-
phosphorylation in response to VEGF (Supplementary Fig. 8e). Similar to the results 
observed after transduction of VEGF-R2(Δ450C), this catalytically inactive mutant fails to 
complex with PDGF-Rβ after dual growth factor treatment, demonstrating that VEGF-R2 
activity is required for interaction with PDGF-Rβ (Fig. 3e). Importantly, complex formation 
is still observed when two VEGF-R2 effector sites (Y1174 and Y1212) are mutated.
Tumors express high levels of VEGF and as a result develop tortuous, leaky and immature 
blood vessels.16–17 Anti-VEGF therapy results in vessel normalization characterized by 
increased pericyte coverage, tumor perfusion and chemotherapeutic sensitivity.18 To 
investigate VEGF’s role in tumor vessel normalization, we examined the vasculature of 
fibrosarcomas that either express or lack VEGF.19 Similar to results from anti-VEGF 
therapy, VEGF−/− tumors produce mature vessels with extensive pericyte coverage, 
whereas wild type (VEGF+/+) tumors develop an immature tumor vasculature with minimal 
pericyte coverage (Fig. 4a–b). Importantly, dual expression of PDGF-Rβ and VEGF-R2 
appears limited to α-SMA+ perivascular cells (Fig. Supplementary Fig. 11b). Interestingly, 
the VEGF-R2/PDGF-Rβ complex is only detected in lysates of VEGF+/+ tumors, which 
feature an immature vasculature (Fig. 4c). By contrast, complex formation is attenuated in 
VEGF−/− tumors, concomitant with increased PDGF-Rβ phosphorylation (Fig. 4c) and 
decreased VEGF-R2 phosphorylation (Supplementary Fig. 11a). Next, we implanted human 
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pancreatic tumor cells orthotopically into the tail of the mouse pancreas and allowed tumors 
to develop for two weeks. Analysis of immunoprecipitated protein from these tumors 
demonstrated PDGF-Rβ/VEGF-R2 complex formation (Supplementary Fig. 12a). While the 
tumor cells within these tissues express negligible levels of VEGF or PDGF receptors we 
did observe co-expression of VEGF-R2 and PDGF-Rβ on perivascular cells that co-stain 
with alpha-smooth muscle actin (Supplementary Fig. 12b–c). Taken together, these studies 
demonstrate that VEGF can induce the formation of a VEGF-R2/PDGF-Rβ complex 
implicated both in the suppression of pericyte function and in the regulation of tumor 
angiogenesis. Our findings support a mechanism where VEGF inhibits pericyte function and 
blood vessel maturation through the induction of a VEGF-R2/PDGF-Rβ complex, and may 
in part, explain the molecular basis of anti-VEGF therapy in cancer patients.
Methods Summary
HUVECs, HMVECs, HAECs, and NHDFs were acquired from Clonetics. Human aortic 
VSMCs were isolated from three donors (Clonetics and Cascade Biologicals). The pericyte 
line C3 10T1/2 (clone 8) was acquired from ATCC. Murine lung endothelial cells (MLECs) 
were isolated by immunoselection using Dynal magnetic beads (Invitrogen). For in vitro 
studies, unless otherwise indicated, PDGF-BB, VEGF-165, and FGF-2 were used at 20 
ng/mL, 40 ng/ml, and 50 ng/ml, respectively. 500 ng and 100 ng of growth factor was used 
for Matrigel and CAM experiments, respectively. Epitope-tagged mutant receptor constructs 
and adenoviruses were generated using standard cloning techniques and validated by DNA 
sequencing. The procedures for CAM,20 Matrigel,21 and murine fibrosarcoma19 
experiments were performed with Institutional approval as previously reported or with slight 
modifications. Full Methods accompany this paper.
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Figure 1. VEGF Inhibits PDGF-mediated Angiogenesis through VEGF-R2
a, Upper: vessel growth into Matrigel as measured by CD-31+ area, *P<0.02. Bottom: 
branch points quantified on filter paper impregnated with saline or growth factors placed on 
embryonic day 10 Chick CAMs; *P<0.02, **p<0.05, results from one-way ANOVA. 
Further images are displayed in Supplementary Fig. 1d. b, Upper: vessel growth into 
Matrigel as in a, with the application of inhibitors; *P<0.001, **P<0.001. Bottom: branch 
points quantified on filter paper impregnated with saline or growth factor as in a, with the 
application of inhibitors; *P<0.02, **P<0.05 *results from two-way ANOVA. Right: 
confocal microscopy of Matrigel from mice injected intravenously with fluorescent 
Griffonia lectin; Scale bar, 100 μm c, CD-31+ area quantified by image analysis of Matrigel 
(right panel) impregnated with saline or growth factor implanted into mice infected with 
adenovirus expressing GFP only or GFP and truncated VEGF-R2 (Δ450C); Scale bar, 200 
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μm; *P<0.001, **P<0.001, results from one-way ANOVA. All error bars ± S.D; n>5 per 
group in all panels.
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Figure 2. VEGF Disrupts Pericyte Coverage/VSMC Activation through VEGF-R2
a, Right: confocal microscopy images of reconstituted basement membrane impregnated 
with growth factors from mice perfused with fluorescent Griffonia lectin (green), stained for 
α-SMA (red). Left: pericyte coverage as assessed by α-SMA/lectin co-localization; 
*P<0.01, results from one-way ANOVA, n=6/group. b, Representative proliferation (upper, 
*P<0.001) and migration assays (lower, *P<0.001); *results from one-way ANOVA. c, 
Representative VSMC proliferation (upper, *P<0.01; **P<0.05) and migration (lower, 
*P<0.001, **P<0.001) assays performed after siRNA-mediated knock-down of VEGF 
receptors normalized to PBS control where indicated; results from one-way ANOVA, n>3 
experiments. All error bars ± S.D.
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Figure 3. An Inducible VEGF-R2/PDGF-Rβ Complex Forms in VSMC
a, Immunoblot analysis of anti-PDGF-Rβ immunoprecipitated lysates from serum-starved 
VSMCs subjected to siRNA-mediated VEGF receptor knock-down. b, Upper: Immunoblot 
analysis of anti-PDGF-Rβ immunoprecipitated lysates from serum-starved NHDFs (VEGF-
R2 null) infected with adenovirus. Immunoblots represent at least three similar experiments. 
Lower left: Representative proliferation (left) and migration (right) experiments with VEGF-
R2 reconstituted NHDFs; *P<0.001, P<0.02, results from one-way ANOVA, n>3 separate 
experiments. c, Representative reciprocal co immunoprecipitation followed by immunoblot 
analysis with lysates derived from serum-starved VSMCs pre-treated with either control or 
VEGF-R2 inhibitor or d, serum-starved NHDFs transduced with truncated VEGF-R2 
adenovirus or e, NHDFs transduced with VEGF-R2 catalytic site (Y1052F and Y1057F) and 
effector site mutants (Y1174F and Y1212F). IB, immunoblot; IP, immunoprecipitation; 
WCL, whole cell lysate; c-t, C-terminus. Immunoblots are representative of at least three 
similar experiments; mutant receptors are characterized in Supplementary Fig. 8.
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Figure 4. VEGF Loss Attenuates VEGF-R2/PDGF-Rβ Complex Formation and Tumor Vessel 
Maturation
a, Confocal microscopy of WT (VEGF+/+) and KO (VEGF−/−) fibrosarcomas 
demonstrating histological markers of vascular maturity and phosphorylated PDGF-Rβ 
(Y751) with b, image analysis; P<*0.01, **P<0.001, ***P<0.05, results from unpaired t-
test, n>3 animals/group. c, anti-PDGF-Rβ immunoprecipitated tumor lysates derived from 
VEGF+/+ and VEGF−/− tumors.
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